Kailera Therapeutics, Inc.

NASDAQ:KLRA

Biotechnology

Healthcare
$11.79 +2.66%

+$0.51 today

Market cap
$1.53B
Beta
0.00
52W Low $18.50High $28.23

Volume 0.42M

Average 0.80M

KLRA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Kailera Therapeutics, Inc.NASDAQ: KLRA

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow of $667.03M in Q2 FY2026

Q2 FY2026 financing cash flow was $667.03M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$667.03M+22483.4% QoQ
Last fiscal yearDec 2025
$598.66M— YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
598.66M USD
Year-over-year change
—

Financing Cash Flow vs competitors

How KLRA compares with its peers on the latest reported figures

  • KLRA's FY2025 financing cash flow of $598.66M is the largest of the 10 companies compared; the peer median is $108.9M.
KLRA Competitors Peer median
Financing Cash Flow for KLRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KLRAKailera Therapeutics, Inc.FY2025$598.66M ———
ALTAltimmune, Inc.LTM Mar 2026$251.49M +466.1%+53.9%698594.4%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$189.81M +0.4%+60.3%—
BIOABioAge Labs, Inc.LTM Mar 2026$136.68M -35.4%+66.2%1325.0%
VKTXViking Therapeutics, Inc.LTM Jun 2026$111.25M +2441.0%+163.8%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$108.9M +27468.4%+189.0%—
VTVTvTv Therapeutics Inc.LTM Mar 2026$77.44M +3044.2%+76.9%210.2%
BMEABiomea Fusion, Inc.LTM Mar 2026$64.53M +1243.2%+279.8%—
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$41.68M -91.1%-57.8%585.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$15.14M -54.2%——
Peer median (excluding KLRA) $108.9M+466.1%+71.6%955.2%

Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kailera Therapeutics, Inc.

NASDAQ:KLRA

Intrinsic Alpha fair value

Locked

Current Price

$11.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.